Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer

Document Details

Document Type
Pub Defense Publication
Publication Date
Apr 09, 2019
Source ID
10.1021/acs.jmedchem.9b00327

Entities

People

  • Chao Wang
  • Chenchang Li
  • Cheng Zhang
  • Donghai Wu
  • Hong-Wu Chen
  • Jinxin Xu
  • Junjian Wang
  • Kerry Loomes
  • Lingjiao Zou
  • Qiu Li
  • Rui Wang
  • Xiaojuan Hao
  • Xiaoqian Xue
  • Xishan Wu
  • Yan Zhang
  • Yong Xu
  • Yudan Shi
  • Zenghong Huang

Organizations

  • Chinese Academy of Sciences
  • Commonwealth Scientific and Industrial Research Organisation
  • Guangzhou Medical University
  • Huizhou University
  • Jilin University
  • Ministry of Science and Technology of the People's Republic of China
  • National Cancer Institute
  • National Natural Science Foundation of China
  • Prostate Cancer Foundation
  • Sun Yat-sen University
  • United States Department of Defense
  • University of Auckland
  • University of Chinese Academy of Sciences